基因组编辑
生物
基因
相(物质)
计算机科学
计算生物学
化学
遗传学
细胞生物学
医学
突变
作者
Luke Joseph Laffin,Stephen James Nicholls,Steven E. Nissen
摘要
To the Editor: Laffin and colleagues (Nov. 27 issue) 1 report impressive short-term lipid lowering with a single intravenous dose of CTX310 — a lipid-nanoparticle–encapsulated CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats–Cas9 endonuclease) therapy targeting hepatic ANGPTL3 — in patients with refractory dyslipidemia. In their article, the investigators highlight the “one-and-done, potentially transformative” use of this therapy. I agree with this concept but warn that these data should be interpreted within a cautious framework for irreversible gene editing in patients with common cardiometabolic diseases. First, the long-term hepatic safety of ANGPTL3 suppression remains unclear. In the Supplementary Appendix of the article, . . .
科研通智能强力驱动
Strongly Powered by AbleSci AI